Wuhan General Group (OTCMKTS:WUHN) & DNOW (NYSE:DNOW) Head to Head Analysis

DNOW (NYSE:DNOW) and Wuhan General Group (OTCMKTS:WUHN) are both industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for DNOW and Wuhan General Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DNOW	0	1	2	1	3.00
Wuhan General Group	0	0	0	0	0.00

DNOW currently has a consensus target price of $17.67, suggesting a potential upside of 23.37%. Given DNOW’s stronger consensus rating and higher probable upside, equities analysts clearly believe DNOW is more favorable than Wuhan General Group.

Risk & Volatility

DNOW has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Wuhan General Group has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Valuation and Earnings

This table compares DNOW and Wuhan General Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DNOW	$2.37 billion	0.63	$81.00 million	$0.87	16.46
Wuhan General Group	N/A	N/A	N/A	N/A	N/A

DNOW has higher revenue and earnings than Wuhan General Group.

Insider & Institutional Ownership

97.6% of DNOW shares are owned by institutional investors. 2.7% of DNOW shares are owned by insiders. Comparatively, 61.1% of Wuhan General Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares DNOW and Wuhan General Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DNOW	3.91%	9.35%	6.55%
Wuhan General Group	N/A	N/A	N/A

Summary

DNOW beats Wuhan General Group on 10 of the 11 factors compared between the two stocks.

About DNOW

DNOW Inc. distributes downstream energy and industrial products for petroleum refining, chemical processing, LNG terminals, power generation utilities, and customer on-site locations in the United States, Canada, and internationally. The company provides consumable maintenance, repair, and operating supplies; pipes, manual and automated valves, fittings, flanges, gaskets, fasteners, electrical instrumentations, artificial lift, pumping solutions, valve actuation and modular process, and measurement and control equipment; and mill supplies, tools, safety supplies, and personal protective equipment, as well as artificial lift systems, coatings, and miscellaneous expendable items. It also offers original equipment manufacturer equipment, including pumps, generator sets, air compressors, dryers, blowers, mixers, and valves; modular oil and gas tank battery solutions; and application systems, work processes, parts integration, optimization solutions, and after-sales support services. In addition, the company provides supply chain and materials management; inventory planning and management, procurement, and warehouse management, as well as solutions for logistics, point of issue technology, project management, business process, and performance metrics reporting services. It serves customers in the upstream, midstream, and downstream sectors of the energy industry, including drilling contractors, well-servicing companies, independent and national oil and gas companies, midstream operators, and refineries, as well as petrochemical, chemical, utilities, RNG facilities, and other downstream energy processors; and industrial and manufacturing companies. The company was formerly known as NOW Inc. and changed its name to DNOW Inc. in January 2024. DNOW Inc. was founded in 1862 and is headquartered in Houston, Texas.

About Wuhan General Group

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.